Efficacy of probucol for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label pilot study

Hepatology Research

Volumn 44, Issue 4, 2014, Pages 429-435

  Ishitobi, Tomokazu ^a   Hyogo, Hideyuki ^a   Tokumo, Hironori ^c   Arihiro, Koji ^b   Chayama, Kazuaki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c JA Hiroshima General Hospital   (Japan)

Author keywords

Dyslipidemia; Non alcoholic steatohepatitis; Oxidative stress; Probucol

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ADIPONECTIN; COLLAGEN TYPE 4; COLLAGEN TYPE 7; FERRITIN; HEMOGLOBIN A1C; HYALURONIC ACID; LEPTIN; PROBUCOL;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; FIBROSIS; FOLLOW UP; HUMAN; HUMAN TISSUE; INTRAABDOMINAL FAT; LIVER BIOPSY; LIVER FUNCTION TEST; MALE; MIDDLE AGED; MONOTHERAPY; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; PRIORITY JOURNAL;

EID: 84898597579     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12135     Document Type: Article

References (47)

1. Eguchi Y, Hyogo H, Ono M etal. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol 2012; 47: 586-595.
2. Teli MR, James OF, Burt AD etal. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714-1719.
3. Dam-Larsen S, Franzmann M, Andersen IB etal. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004; 53: 750-755.
4. Matteoni CA, Younossi ZM, Gramlich T etal. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
5. James O, Day C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet 1999; 353: 1634-1636.
6. Chitturi S, Abeygunasekera S, Farrell GC etal. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-379.
7. Marchesini G, Brizi M, Bianchi G etal. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-1850.
8. Hui JM, Farrell GC. Clear messages from sonographic shadows? Links between metabolic disorders and liver disease, and what to do about them. J Gastroenterol Hepatol 2003; 18: 1115-1117.
9. Marchesini G, Bugianesi E, Forlani G etal. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923.
10. Musso G, Gambino R, Cassader M etal. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52: 79-104.
11. Look AHEAD Research Group, Wadden TA, West DS etal. The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity 2006; 14: 737-752.
12. American Gastroenterological Association. American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1702-1704.
13. Ibrahim MA, Kelleni M, Geddawy A. Nonalcoholic fatty liver disease: current and potential therapies. Life Sci 2013; 92: 114-118.
14. Kimura Y, Hyogo H, Yamagishi S etal. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol 2010; 45: 750-757.
15. Hyogo H, Yamagishi SI, Maeda S etal. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-a-lowering property. Dig Liver Dis 2012; 44: 492-496.
16. Merat S, Aduli M, Kazemi R etal. Liver histology changes in nonalcoholic steatohepatitis after one year of treatment with probucol. Dig Dis Sci 2008; 53: 2246-2250.
17. Merat S, Malekzadeh R, Sohrabi MR etal. Probucol in the treatment of nonalcoholic steatohepatitis an open-labeled study. J Clin Gastroenterol 2003; 36: 266-268.
18. Merat S, Malekzadeh R, Sohrabi MR etal. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatol 2003; 38: 414-418.
19. Tokushige K, Hashimoto E, Yatsuji S etal. Combined pantethine and probucol therapy for Japanese patients with non-alcoholic steatohepatitis. Hepatol Res 2007; 37: 872-877.
20. Whalan DJ. The ethics and morality of clinical trials in man. Med J Aust 1975; 1: 491-494.
21. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219.
22. Japanese Society for the Study of Obesity. New criteria for "obesity disease" in Japan. Circ J 2002; 66: 987-992.
23. Ricci C, Longo R, Gioulis E etal. Noninvasive in vivo quantitative assessment of fat content in human liver. J Hepatol 1997; 27: 108-113.
24. Matthews DR, Hosker JP, Rudenski AS etal. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
25. The Committee of Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010; 1: 212-228.
26. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009; 32: 1327-1334.
27. World Health Organization. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of A WHO/IDF Consultation. Geneva: World Health Organization, 2006.
28. Brunt EM, Janney CG, Di Bisceglie AM etal. Non-alcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
29. Kleiner DE, Brunt EM, Van Natta M etal. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
30. Park H, Shima T, Yamaguchi K etal. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 101-107.
31. Begriche K, Massart J, Robin MA etal. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology 2013 (in press).
32. Sumida Y, Nakashima T, Yoh T etal. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. J Hepatol 2003; 38: 32-38.
33. Sanyal AJ, Chalasani N, Kowdley KV etal. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-1685.
34. Noguchi N, Niki E. Phenolic antioxidants: a rationale for design and evaluation of novel antioxidant drug for atherosclerosis. Free Radic Biol Med 2000; 28: 1538-1546.
35. Tardif JC, Côté G, Lespe'rance J etal. The multivitamins and probucol study group. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997; 337: 365-372.
36. Kaul N, Siveski-Iliskovic N, Thomas TP etal. Probucol improves antioxidant activity and modulates development of diabetic cardiomyopathy. Nutrition 1995; 11: 551-554.
37. Ito M, Suzuki Y, Ishihara M etal. Anti-ulcer effects of antioxidants: effect of probucol. Eur J Pharmacol 1998; 354: 189-196.
38. Seki S, Kitada T, Sakaguchi H. Clinicopathological significance of oxidative cellular damage in non-alcoholic fatty liver diseases. Hepatol Res 2005; 33: 132-134.
39. Paradis V, Perlemuter G, Bonvoust F etal. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001; 34: 738-744.
40. Hyogo H, Yamagishi S, Iwamoto K etal. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007; 22: 1112-1119.
41. Iwamoto K, Kanno K, Hyogo H etal. Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. J Gastroenterol 2008; 43: 298-304.
42. Kimura Y, Hyogo H, Ishitobi T etal. Postprandial insulin secretion pattern is associated with histological severity in non-alcoholic fatty liver disease patients without prior known diabetes mellitus. J Gastroenterol Hepatol 2011; 26: 517-522.
43. Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol 2011; 46: 63-69.
44. Adams LA, Sanderson S, Lindor KD etal. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42: 132-138.
45. Ekstedt M, Franz LE, Mathiesen UL etal. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873.
46. Argo CK, Northup PG, Al-Osaimi AM etal. Systematic review of risk factors for fibrosis progression in nonalcoholic steatohepatitis. J Hepatol 2009; 51: 371-379.
47. Wong VW, Wong GL, Choi PC etal. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59: 969-974.